- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Senate passes Drug Quality and Security Act
- Diplomat becomes distributor of recently approved cancer drug
- FDA advisory panel to consider OTC status of NSAIDs
- FDA advisory committees turn down Primatene HFA application for OTC status
ATLANTA — The Food and Drug Administration has approved a patch for treating restless legs syndrome and Parkinson's disease.
UCB announced the FDA approval of Neupro (rotigotine) transdermal system advanced-stage idiopathic Parkinson's and moderate-to-severe restless legs syndrome.
"Neupro represents an innovation in the treatment of Parkinson's disease and restless legs syndrome," UCB chief medical officer and EVP global projects and development Iris Loew-Friedrich said. "UCB is thrilled to make Neupro available to patients living with these serious diseases."